The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma

WD repeat-containing protein 1 (WDR1) regulates the cofilin 1 (CFL1) activity, promotes cytoskeleton remodeling, and thus, facilitates cell migration and invasion. A previous study reported that autoantibodies against CFL1 and β-actin were useful biomarkers for diagnosing and predicting the prognosis of patients with esophageal carcinoma. Therefore, the present study aimed to evaluate the serum levels of anti-WDR1 antibodies (s-WDR1-Abs) combined with serum levels of anti-CFL1 antibodies (s-CFL1-Abs) in patients with esophageal carcinoma. Serum samples obtained from 192 patients with esophageal carcinoma and other solid cancers. And s-WDR1-Ab and s-CFL1-Ab titers were analyzed using the amplified luminescent proximity homogeneous assay-linked immunosorbent assay. Compared with those of healthy donors, the s-WDR1-Ab levels were significantly higher in the 192 patients with esophageal, whereas these were not significantly higher in the samples from patients with gastric, colorectal, lung, or breast cancer. In 91 patients treated with surgery, sex, tumor depth, lymph node metastasis, stage and C-reactive protein levels were significantly associated with overall survival, as determined using the log-rank test, whereas the squamous cell carcinoma antigen, p53 antibody and s-WDR1-Ab levels tended to be associated with a worse prognosis. Although no significant difference was observed in the survival between the positive and negative groups of s-WDR1-Abs or s-CFL1-Abs alone in the Kaplan-Meier test, the patients in the s-WDR1-Ab-positive and s-CFL1-Ab-negative groups exhibited a significantly poorer prognosis in the overall survival analysis. On the whole, the present study demonstrates that the combination of positive anti-WDR1 antibodies with negative anti-CFL1 antibodies in serum may be a poor prognostic factor for patients with esophageal carcinoma.

[1]  Y. Iwadate,et al.  Low anti-CFL1 antibody with high anti-ACTB antibody is a poor prognostic factor in esophageal squamous cell carcinoma , 2022, Esophagus.

[2]  H. Shimada,et al.  Prognostic impact of carcinoembryonic antigen in 1822 surgically treated esophageal squamous cell carcinoma: multi-institutional study of the Japan Esophageal Society. , 2022, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[3]  T. Hiwasa,et al.  Serum Anti-BRAT1 is a Common Molecular Biomarker for Gastrointestinal Cancers and Atherosclerosis , 2022, Frontiers in Oncology.

[4]  Kentaro Tanaka,et al.  The C29-C34 parts of antitumor macrolide aplyronine A serve as versatile actin-affinity tags. , 2021, Chemical communications.

[5]  H. Shimada,et al.  Identification of serum anti-striatin 4 antibodies as a common marker for esophageal cancer and other solid cancers. , 2021, Molecular and clinical oncology.

[6]  Y. Iwadate,et al.  Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer , 2021, Frontiers in Oncology.

[7]  Yingying Wang,et al.  Hhex inhibits cell migration via regulating RHOA/CDC42-CFL1 axis in human lung cancer cells , 2021, Cell communication and signaling : CCS.

[8]  T. Hiwasa,et al.  Novel serum autoantibodies against ß-actin (ACTB) in amyotrophic lateral sclerosis , 2021, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[9]  Silke D. Werle,et al.  Unraveling the Molecular Tumor-Promoting Regulation of Cofilin-1 in Pancreatic Cancer , 2021, Cancers.

[10]  Rika Nakamura,et al.  Serum anti‐LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases , 2020, Cancer science.

[11]  R. Safaralizadeh,et al.  Overexpression of CFL1 in gastric cancer and the effects of its silencing by siRNA with a nanoparticle delivery system in the gastric cancer cell line , 2020, Journal of cellular physiology.

[12]  Takeshi Kimura,et al.  Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction , 2017, Oncotarget.

[13]  R. Weinberg,et al.  Emerging Biological Principles of Metastasis , 2017, Cell.

[14]  R. Qin,et al.  High expression of WDR1 in primary glioblastoma is associated with poor prognosis. , 2016, American journal of translational research.

[15]  P. Wan,et al.  AIP1-mediated actin disassembly is required for postnatal germ cell migration and spermatogonial stem cell niche establishment , 2015, Cell Death and Disease.

[16]  Y. Iwadate,et al.  Identification of stroke-associated-antigens via screening of recombinant proteins from the human expression cDNA library (SEREX) , 2015, Journal of Translational Medicine.

[17]  H. Agaisse,et al.  Actin network disassembly powers dissemination of Listeria monocytogenes , 2014, Journal of Cell Science.

[18]  H. Salvesen,et al.  Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue. , 2013, Biochimica et biophysica acta.

[19]  Masahiko Kato,et al.  Autoantibody against WD repeat domain 1 is a novel serological biomarker for screening of thyroid neoplasia , 2013, Clinical endocrinology.

[20]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[21]  K. Ohashi,et al.  Cytochalasin D acts as an inhibitor of the actin-cofilin interaction. , 2012, Biochemical and biophysical research communications.

[22]  H. Matsubara,et al.  Identification of a novel SEREX antigen family, ECSA, in esophageal squamous cell carcinoma , 2011, Proteome Science.

[23]  Yan Cheng,et al.  Identification of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1. , 2009, Cancer letters.

[24]  H. Matsubara,et al.  Identification of Makorin 1 as a novel SEREX antigen of esophageal squamous cell carcinoma , 2009, BMC Cancer.

[25]  T. Mitchison,et al.  Caspase-11 regulates cell migration by promoting Aip1–Cofilin-mediated actin depolymerization , 2007, Nature Cell Biology.

[26]  H. Shimada,et al.  Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma. , 2006, International journal of oncology.

[27]  H. Matsubara,et al.  Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma , 2004, International journal of cancer.

[28]  H. Matsubara,et al.  Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. , 2003, Surgery.

[29]  H. Shimada,et al.  Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. , 2003, Cancer.

[30]  M. Arima,et al.  Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma , 2000, Cancer.

[31]  A. Müller-Taubenberger,et al.  Daip1, a Dictyostelium Homologue of the Yeast Actin-Interacting Protein 1, Is Involved in Endocytosis, Cytokinesis, and Motility , 1999, The Journal of cell biology.

[32]  M. Pfreundschuh,et al.  Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Noh,et al.  Proteomic analysis of breast cancer tissue reveals upregulation of actin‐remodeling proteins and its relevance to cancer invasiveness , 2009, Proteomics. Clinical applications.